XDNA: CRISPR Start-Ups Are Being Courted by Big Pharma – Mammoth & Bayer

January 10, 2022 by Kevin Kelly

CRISPR & Gene Editing companies are making waves in 2022, including start-ups, which is validating the technology’s promise on disrupting healthcare.

News coming out of Berlin, Germany and Brisbane, California USA from Bayer AG and Mammoth Biosciences, Inc., is showing how “Big Pharma” is looking to partner with CRISPR start-up company. In a joint press release, the companies announced a strategic collaboration and option agreement for the use of Mammoth’s CRISPR systems to develop in vivo gene-editing therapies.

The XDNA index has leading public companies who are developing in vivo gene editing technology.

The statement said:

Mammoth Biosciences’ groundbreaking gene-editing technology is a key enabling technology, as well as a stand-alone therapeutic modality. It will significantly enhance Bayer’s efforts to develop transformative therapies for patients faster and strengthen the company’s recently established new cell and gene therapy platform. Under the terms of the agreement the two companies will start their collaboration with a focus on liver-targeted diseases.

Barron’s covered the news by stating:

The week began with Germany’s Bayer (BAYN.Germany) saying on Sunday that it will pay $40 million, and potentially $1 billion more, to work with Mammoth BioSciences, a privately held venture co-founded by Jennifer Doudna—who won a Nobel Prize with Emmanuelle Charpentier for discovering the Crispr-Cas gene-editing technology. Monday, Pfizer unveiled a $1.3 billion partnership with the gene-editing firm Beam Therapeutics (BEAM).

To learn more about CRISPR & Gene Editing please visit the XDNA Index page or watch the video below:

It is not possible to invest directly in an index. Exposure to an asset class represented by an index is available through investable instruments based on that index. Strategic Investments does not sponsor, endorse, sell, promote or manage any investment fund or other investment vehicle that is offered by third parties and that seeks to provide an investment return based on the performance of any index. Strategic Investments licenses its indices to third parties for the creation of investment funds or other vehicles, such as exchange-traded funds (ETFs), exchange-traded notes (ETNs), institutional asset mandates, and structured notes.

The information contained does not reflect the performance of any fund or account managed or serviced by Strategic Investments, and there is no guarantee that investors will experience the type of performance reflected above. There is no guarantee that any historical trend illustrated herein will be repeated in the future, and there is no way to predict precisely when such a trend will begin. There is no guarantee that any market forecast made in this commentary will be realized. The mention of specific securities is not a recommendation or solicitation for any person to buy, sell or hold any particular security and should not be relied upon as investment advice. The views and opinions in the preceding commentary are as of the date of publication and are subject to change without notice. This material represents an assessment of the market environment at a specific point in time, should not be relied upon as investment advice, is not intended to predict or depict performance of any investment and does not constitute a recommendation or an offer for a particular security. We consider the information in this presentation to be accurate, but we do not represent that it is complete or should be relied upon as the sole source of suitability for investment.